Let’s delve into the details of each of the evaluated factors, but first, for a quick background: With a $917 Bil market cap, Eli Lilly offers pharmaceuticals globally, focusing on treatments for cancers, rheumatoid arthritis, psoriasis, and other autoimmune disorders.

Trump announces deal with Eli Lilly, Novo Nordisk to lower cost of GLP-1 weight loss drugs Wegovy, Zepbound. Here's what to know and Medicare coverage

Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.

Eli Lilly stock has regained all-time highs, outpacing rivals in the obesity drug market. Click here to read my latest analysis of LLY.

President Donald Trump announced that his administration has finally struck a deal with Novo Nordisk and Eli Lilly to reduce the cost of their GLP-1 weight loss drugs, Wegovy and Zepbound. Currently,

Eli Lilly and Novo Nordisk May Soon Sell Weight Loss Drugs on the Planned TrumpRx. Could This Further Boost the Healthcare Giants' Stocks? Investors will be watching what Trump makes happen.

Researchers monitoring the brain activity of a patient with a severe binge-eating problem reported that Eli Lilly's GLP-1 weight-loss drug appeared to temporarily suppress food-craving ​signals in the "reward center" of the brain.

The Trump administration is currently negotiating with Danish pharmaceuticals, including Eli Lilly and Novo Nordisk to minimize the cost of glucagon-like peptide-1 GLP-1 drugs — weight-loss pills.Several credible sources informed ABC

Novo Nordisk A/S is undercutting arch-rival Eli Lilly & Co. on obesity drugs for cash-pay patients, showing its willingness to compete on price as it tries to claw back a larger share of the US market.

Eli Lilly’s Zepbound push is getting a “Queer Eye” makeover with the help of fashion expert Tan France, who is joining the drugmaker to knit together a collection of stories that uses clothing to u | The fashion expert joins Lilly for its multimedia "Changing the Thread Collection,

Lilly is reportedly shifting its 50,000 employees to Rightway, a fintech-driven pharmacy benefit manager, starting January 1. ・The move follows CVS Caremark’s decision to drop Lilly’s Zepbound from its preferred list in favor of Novo Nordisk’s Wegovy.